-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1

Benzinga·09/03/2026 13:09:08
Listen to the news
Wedbush analyst David Nierengarten downgrades TScan Therapeutics (NASDAQ:TCRX) from Outperform to Neutral and lowers the price target from $5 to $1.